Clinical Laserthermia Systems announces enrollment completion of initial phase and extension of clinical trial at Radboud University Medical Center
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announced that Radboud University Medical Center in Nijmegen (RUMC), the Netherlands, has completed patient enrollment of the initial phase and extended the investigator initiated trial to evaluate feasibility, usability and safety of CLS’s TRANBERG® Thermal Therapy System with ThermoguideTM Workstation for MR guided focal laser ablation (MRgFLA) of low-to-intermediate-risk prostate cancer.RUMC has safely treated ten patients within the investigator initiated study using the TRANBERG® Thermal Therapy